Cannabinoids are specific chemical compounds found in cannabis, such as tetrahydrocannabinol (THC) and cannabidiol (CBD). Research is increasingly su ...

In a report released today, Graig Suvannavejh from Mizuho Securities reiterated a Buy rating on Insmed, with a price target of $130.00. The company’s shares opened today at $109.83. Take advantage of ...

The postoperative pain management market is witnessing steady growth, driven by the rising number of surgical procedures globally and increasing awar ...

The risk for several adverse health outcomes, including PTSD, traumatic brain injury and anxiety, was heightened among active ...

Axsome Therapeutics reported record total product revenues of $150 million for the quarter, marking a 72% increase year-over-year and a 24% increase quarter-over-quarter. This impressive growth ...

Q2 2025 Earnings Call Transcript August 4, 2025 Axsome Therapeutics, Inc. beats earnings expectations. Reported EPS is $-0.92 ...

Axsome Therapeutics reported quarterly losses of 47 cents per share compared to analyst consensus estimate of losses of $1.07 per share. The company reported quarterly sales of $150.04 million which ...

Axsome Therapeutics Inc (AXSM) reports a 72% year-over-year revenue increase, driven by strong product sales and strategic ...

Discover Axsome Therapeutics' Q2 2025 earnings highlights, including 72% revenue growth, new product launch SYMBRAVO, and promising neuroscience ...

Axsome (AXSM) delivered earnings and revenue surprises of +8.00% and +7.47%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

TRUNNANO, a leading global supplier of high-performance nanomaterials and advanced chemical materials, is proud to announce the launch of its latest product: ...